Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;22(8):968-974.
doi: 10.1016/j.jmoldx.2020.06.003. Epub 2020 Jun 19.

Responding to the Challenges of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Perspectives from the Association for Molecular Pathology Infectious Disease Subdivision Leadership

Frederick S Nolte  1 , N Esther Babady  2 , Blake W Buchan  3 , Gerald A Capraro  4 , Erin H Graf  5 , Amy L Leber  6 , Erin McElvania  7 , Joseph D C Yao  8
Affiliations
Review

Responding to the Challenges of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Perspectives from the Association for Molecular Pathology Infectious Disease Subdivision Leadership

Frederick S Nolte et al. J Mol Diagn. 2020 Aug.

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Mol Diagn. 2020 Oct;22(10):1308. doi: 10.1016/j.jmoldx.2020.08.001. Epub 2020 Aug 28. J Mol Diagn. 2020. PMID: 32866431 Free PMC article. No abstract available.

Abstract

Clinical molecular laboratory professionals are at the frontline of the response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, providing accurate, high-quality laboratory results to aid in diagnosis, treatment, and epidemiology. In this role, we have encountered numerous regulatory, reimbursement, supply-chain, logistical, and systems challenges that we have struggled to overcome to fulfill our calling to provide patient care. In this Perspective from the Association for Molecular Pathology Infectious Disease Subdivision Leadership team, we review how our members have risen to these challenges, provide recommendations for managing the current pandemic, and outline the steps we can take as a community to better prepare for future pandemics.

PubMed Disclaimer

References

    1. Nowak J.A., Kaul K.L. The role of community molecular diagnostics laboratories in the H1N1 pandemic. J Mol Diagn. 2009;11:369–370. - PMC - PubMed
    1. Jernigan D.B., Lindstrom S.L., Johnson J.R., Miller J.D., Hoelscher M., Humes R., Shively R., Brammer L., Burke S.A., Villanueva J.M., Balish A., Uyeki T., Mustaquim D., Bishop A., Handsfield J.H., Astles R., Xu X., Klimov A.I., Cox N.J., Shaw M.W. Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. Clin Infect Dis. 2011;52(Suppl 1):S36–S43. - PubMed
    1. Crawford J.M., Stallone R., Zhang F., Gerolimatos M., Korologos D.D., Sweetapple C., De Geronimo M., Dlugacz Y., Armellino D.M., Ginocchio C.C. Laboratory surge response to pandemic (H1N1) 2009 outbreak, New York City metropolitan area, USA. Emerg Infect Dis. 2010;16:8–13. - PMC - PubMed
    1. Meltzer M.I., McNeill K.M., Miller J.D. Laboratory surge capacity and pandemic influenza. Emerg Infect Dis. 2010;16:147–148. - PMC - PubMed
    1. van der Vries E., Jonges M., Herfst S., Maaskant J., Van der Linden A., Guldemeester J., Aron G.I., Bestebroer T.M., Koopmans M., Meijer A., Fouchier R.A.M., Osterhaus A.D.M.E., Boucher C.A., Schutten M. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J Clin Virol. 2010;47:34–37. - PMC - PubMed